Medical Oddities: Dogs share our mortality markers

• by Teraya Smith

• September 2, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

• by Kathryn Wighton

• June 26, 2026

• 3 min

High-Dose Vitamin C Could Pose Risk in Severe Burns

“High-dose intravenous vitamin C administered early after injury did not reduce organ dysfunction or [mortality] and should not be a treatment in severe burns.”

• by Kathryn Wighton

• June 12, 2026

• 3 min

FDA approves dostarlimab for advanced rectal cancer

The accelerated approval adds an immunotherapy option for patients with MSI-H/dMMR stage II/III disease.

• by Mouj Hijazi

• October 19, 2026

• 3 min